De Novo device
ProSense System
Icecure Medical · Cryoablation Device For Local Treatment Of Low-Risk Breast Cancer (QXW, Class II) · First FDA decision Oct 3, 2025, newest Oct 3, 2025Breast cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
3
Naming "ProSense"
MAUDE reports
25
Brand "ProSense", since 2015
PubMed studies
29
Mentioning "ProSense"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ProSense SystemNew device typeBreakthroughDe Novo
DEN220077 · Decided Oct 3, 2025 · 1,080 days after receipt
Device type: Cryoablation Device For Local Treatment Of Low-Risk Breast Cancer (QXW) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Positron Emission Tomography (FDG) for Breast CancerNational analysisReview closedCAG-00094NUpdated Sep 15, 2026
- FDG PET for Breast Cancer (Replaced with Section 220.6.17) - RETIREDNational determinationOn the books220.6.10Updated Jun 7, 2024
- Hyperthermia for Treatment of CancerNational determinationOn the books110.1Updated Apr 17, 2020
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40168Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40179CGS Administrators, LLCUpdated Apr 17, 2026
- MolDX: EndoPredict Breast Cancer Gene Expression TestLocal determinationIn effectL37356CGS Administrators, LLCUpdated Apr 6, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "ProSense", any status and sponsor, newest update first.
IceCure Medical Ltd.Not on our public-company list
NCT07629206 · 400 participants (planned) · Start Jul 17, 2026 · Primary completion Jul 2034
Device: Cryoablation · For: Low-Risk, Early Stage Breast Cancer
Sites: Glendale, California; Portland, Oregon; Germantown, Tennessee
IceCure Medical Ltd.Not on our public-company list
NCT02399124 · 120 participants (planned) · Start Jul 2014 · Primary completion Feb 2026
Device: PROSENSE™ · For: Renal Cell Carcinoma
Sites: Haifa, Israel; Tsrifin, Israel
- Luminal Breast Cancer CryoablationRecruiting
Lucía Graña LópezAcademic, hospital or other
NCT07447414 · 140 participants (planned) · Start Apr 8, 2026 · Primary completion Sep 2028
Device: Cryoablation with liquid nitrogen (Prosense® system) · For: Breast Cancer; Breast Cancer (Early Breast Cancer)
Sites: Lugo, Spain
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ProSense", and for the whole product code for context.
This brand
25 reports: 11 malfunction, 14 injury, 0 death
Whole product code QXW
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- ProSense Cryoablation SystemMalfunction
3008797959-2026-00002 · Received Jul 9, 2026 · Event dated Sep 2, 2026
Device type: Unit, Cryosurgical, Accessories (GEH)
Device problem as coded: Mechanical Problem; Infusion or Flow Problem
Patient problem as coded: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available; No Clinical Signs, Symptoms or Conditions
- PROSENSE CRYOABLATION SYSTEMMalfunction
3008797959-2025-00009 · Received Oct 15, 2025 · Event dated Sep 15, 2025
Device type: Unit, Cryosurgical, Accessories (GEH)
Device problem as coded: Decrease in Pressure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- PROSENSE CRYOABLATION SYSTEMMalfunction
3008797959-2025-00005 · Received Jun 25, 2025 · Event dated May 26, 2025
Device type: Unit, Cryosurgical, Accessories (GEH)
Device problem as coded: Detachment of Device or Device Component
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- PROSENSE CRYOABLATION SYSTEMMalfunction
3008797959-2025-00004 · Received Jun 22, 2025 · Event dated May 23, 2025
Device type: Unit, Cryosurgical, Accessories (GEH)
Device problem as coded: Infusion or Flow Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- PROSENSE CRYOABLATION SYSTEMMalfunction
3008797959-2025-00003 · Received May 11, 2025 · Event dated Apr 15, 2025
Device type: Unit, Cryosurgical, Accessories (GEH)
Device problem as coded: Detachment of Device or Device Component
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ProSense"[tiab]. The summary above synthesizes these.
- Targeted designed variants of alpha-2-macroglobulin (A2M) attenuate cartilage degeneration in a rat model of osteoarthritis induced by anterior cruciate ligament transection.
Zhang Y, Wei X, Browning S, et al. · Arthritis Res Ther · 2017Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- Biochromoendoscopy: molecular imaging with capsule endoscopy for detection of adenomas of the GI tract.
Zhang H, Morgan D, Cecil G, et al. · Gastrointest Endosc · 2008Comparative Study, Research Support, N.I.H., Extramural
- Ex Vivo and In Vivo Noninvasive Imaging of Epidermal Growth Factor Receptor Inhibition on Colon Tumorigenesis Using Activatable Near-Infrared Fluorescent Probes.
Ding S, Blue RE, Moorefield E, et al. · Mol Imaging · 2017
- Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients.
Khan SY, Cole J, Habrawi Z, et al. · Ann Surg Oncol · 2023
- In vivo imaging of tissue-remodeling activity involving infiltration of macrophages by a systemically administered protease-activatable probe in colon cancer tissues.
Onda N, Kemmochi S, Morita R, et al. · Transl Oncol · 2013
- Prospective Clinical Trial on Expanding Indications for Cryosurgery for Early Breast Cancers.
Kwong A, Co M, Fukuma E · Clin Breast Cancer · 2023Research Support, Non-U.S. Gov't
- Detection of local inflammation induced by repeated exposure to contact allergens by use of IVIS SpectrumCT analyses.
Nielsen MM, Schmidt JD, Christensen JP, et al. · Contact Dermatitis · 2017
- Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging.
Scales HE, Ierna M, Smith KM, et al. · Rheumatology (Oxford) · 2016Research Support, Non-U.S. Gov't
- Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma.
Zhou L, El-Deiry W, Wang W, et al. · Oncol Rep · 2012
- Quantitative Longitudinal Imaging of Vascular Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and α(v)β(3) Integrin.
Lin SA, Patel M, Suresch D, et al. · Int J Mol Imaging · 2012
- Target-Specific Imaging of Cathepsin and S100A8/A9 Reflects Specific Features of Malignancy and Enables Estimation of Tumor Malignancy.
Helfen A, Große Hokamp N, Geyer C, et al. · Mol Imaging Biol · 2020Research Support, Non-U.S. Gov't
- Ultrasound-guided cryoablation: Our experience in percutaneous treatment as an alternative to surgery for fibroadenomas of the breast lesions.
Díaz de Bustamante Durbán T, Roca Navarro MJ, Navarro Monforte Y, et al. · Radiologia (Engl Ed) · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.